Wealthfront Advisers LLC Has $3.26 Million Stake in Axon Enterprise, Inc $AXON

Wealthfront Advisers LLC trimmed its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 35.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,733 shares of the biotechnology company’s stock after selling 3,133 shares during the period. Wealthfront Advisers LLC’s holdings in Axon Enterprise were worth $3,256,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in AXON. Vicus Capital increased its holdings in shares of Axon Enterprise by 3.7% in the third quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 14 shares during the last quarter. Evergreen Capital Management LLC increased its holdings in shares of Axon Enterprise by 3.8% in the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares during the last quarter. NorthCrest Asset Manangement LLC increased its holdings in shares of Axon Enterprise by 5.4% in the third quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 16 shares during the last quarter. WPG Advisers LLC increased its holdings in shares of Axon Enterprise by 9.8% in the third quarter. WPG Advisers LLC now owns 190 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 17 shares during the last quarter. Finally, Monte Financial Group LLC increased its holdings in shares of Axon Enterprise by 5.5% in the third quarter. Monte Financial Group LLC now owns 325 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 17 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Trading Up 0.1%

AXON stock opened at $402.31 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53. The company’s 50-day simple moving average is $454.05 and its 200 day simple moving average is $535.39. Axon Enterprise, Inc has a 52 week low of $339.01 and a 52 week high of $885.91. The company has a market capitalization of $32.41 billion, a PE ratio of 264.68, a price-to-earnings-growth ratio of 8.57 and a beta of 1.61.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating the consensus estimate of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The business had revenue of $796.72 million for the quarter, compared to the consensus estimate of $755.29 million. During the same period in the prior year, the company posted $2.08 earnings per share. Axon Enterprise’s revenue was up 38.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Axon Enterprise, Inc will post 1.41 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Erika Nardini sold 198 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total value of $100,302.84. Following the transaction, the director directly owned 1,946 shares in the company, valued at approximately $985,804.68. This represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Isaiah Fields sold 2,000 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the completion of the transaction, the insider owned 55,588 shares in the company, valued at $29,740,135.88. This trade represents a 3.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,855 shares of company stock valued at $7,109,828 in the last three months. Insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

AXON has been the topic of several research reports. Citizens Jmp reiterated a “market outperform” rating and issued a $825.00 price objective on shares of Axon Enterprise in a report on Monday, April 13th. The Goldman Sachs Group decreased their price objective on shares of Axon Enterprise from $720.00 to $625.00 and set a “buy” rating on the stock in a report on Wednesday, April 8th. Morgan Stanley reiterated an “overweight” rating on shares of Axon Enterprise in a report on Wednesday, April 8th. Needham & Company LLC decreased their price objective on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Finally, William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, February 3rd. Sixteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $749.63.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.